Onchocerciasis (Onchocerca volvulus) Infections and Infestations Onchocerciasis
Conditions
Interventions
The treatment was carried out in a previous feasibility trial of community delivered doxycycline treatment. The drug given in the feasibility trial was doxycycline at 100mg/day, once a day for 6 weeks
Sponsors
Liverpool School of Tropical Medicine (UK)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Stage 1 1. Participants of both sexes aged 19 years or above 2. Received either 6 weeks of doxycycline MDA followed by one or two rounds of annual ivermectin MDA or one or two rounds of annual ivermectin MDA alone 3. Willingness to participate in the study by signing the informed consent form Stage 2 1. Participants of both sexes aged 19 years or above 2. Received either 6 weeks of doxycycline MDA followed by one or two rounds of annual ivermectin MDA or one or two rounds of annual ivermectin MDA alone 3. Presence of a minimum of one onchocercoma detected by palpation 4. Good general health without any clinical condition under treatment with long term medication 5. Willingness to participate in the study by signing the informed consent form
Exclusion criteria
Exclusion criteria: For stages 1 and 2: 1. Ivermectin intake since June 2010 (date of last ivermectin MDA) 2. Intake of antibiotics (tetracyclines or rifamycins) for longer that 2 weeks since June 2007 3. Behavioural, cognitive or psychiatric diseases that in the opinion of the trial clinician affects the ability of the participant to understand and cooperate with the study protocol 4. Any other condition that, in the opinion of the investigator (trial clinician), would risk the safety or rights of the participants in the trial or would render the subject unable to comply with the protocol
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| To evaluate whether ultrasonograpy of palpable nodules to detect parasite motility can be used to monitor and evaluate macrofilaricidal activity after doxycycline MDA | — |
Primary
| Measure | Time frame |
|---|---|
| To evaluate the efficacy of doxycycline MDA followed by ivermectin MDA four years after delivery, at the community level (Stage 1) and known infected patients (Stage 2) and validate compliance rate of phase III implementation trial | — |
Countries
Cameroon
Outcome results
None listed